Radiofrequency Ablation in Nodular Thyroid Diseases  by Lee, Ming-Tsang & Wang, Chih-Yuan
Journal of Medical Ultrasound (2013) 21, 62e70Available online at www.sciencedirect.com
journal homepage: www.jmu-onl ine.comREVIEW ARTICLERadiofrequency Ablation in Nodular CME
Thyroid Diseases
CreditsMing-Tsang Lee 1, Chih-Yuan Wang 2*1Division of Endocrinology, Department of Internal Medicine, Far-Eastern Memorial Hospital, and
2Department of Internal Medicine, National Taiwan University Hospital, College of Medicine,
National Taiwan University, 7, Chung-Shan South Road, Taipei, Taiwan, ROCReceived 18 October, 2012; accepted 25 December, 2012
Available online 12 June 2013KEY WORDS
minimally invasive,
nodular goiter,
radiofrequency
ablation,
thyroid cancer* Correspondence to: Dr Chih-Yuan
National Taiwan University, 7, Chung-
E-mail address: cyw1965@gmail.co
0929-6441 ª 2013, Elsevier Taiwan LL
http://dx.doi.org/10.1016/j.jmu.2013Radiofrequency ablation is a minimally invasive technique that can produce tissue coagulation
necrosis effectively and safely in humans with ultrasound or computed tomography guidance.
The most frequent treatment site for radiofrequency ablation to date is the liver for hepato-
cellular carcinoma. Reviewing the history of radiofrequency ablation, we can see the evalua-
tion of electrodes from conventional monopolar electrode to multiprobe arrays, hook
expandable electrodes, and internally cooled electrodes. All of these are trying to ablate
the tumor more widely and completely. From history, we also notice that the target can range
from heart, neurological disorders, and thyroid diseases to a variety of other diseases, in addi-
tion to liver malignancy. Studies have already shown that radiofrequency ablation is an excel-
lent alternative treatment for nodular thyroid disease, including benign and malignant lesions.
For treatment of recurrent well-differentiated thyroid cancer, radiofrequency ablation has
shown good results, such as no recurrence at treatment sites or reduced serum thyroglobulin
level. The possible complications include hoarseness, hematoma, severe pain, esophageal
perforation, or tracheal perforation. The reported rate for major complications in previous
studies is low. Therefore, if the patients have severe comorbidity that is not suitable for reo-
peration for thyroid malignancy, radiofrequency ablation is a good alternative. Furthermore,
radiofrequency ablation can be used for benign thyroid nodules to relieve local compressive
symptoms. Some patients who receive such treatment for cosmetic reasons also show a satis-
factory outcome. Here, we review previous studies about radiofrequency ablation in nodular
thyroid disease in many aspects, such as ablation system, ablation techniques, ablation effi-
cacy, and complications, both in benign thyroid nodules and recurrent thyroid cancer.
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electrode is heated by thermal conduction slowly. TheRadiofrequency ablation is a minimally invasive technique
that can produce tissue coagulation necrosis in humans.
This technique is performed effectively and safely with
ultrasound or computed tomography guidance. It can be
used to treat a variety of lesions in different organs,
including benign and malignant diseases. The most
frequent treatment site of radiofrequency ablation is the
liver for hepatocellular carcinoma. A lot of research and
scientific reports about the efficacy of radiofrequency
ablation in hepatocellular carcinoma have been available
since the 1990s. Some pioneer radiologists have also tried
to treat head and neck neoplasms with radiofrequency
ablation. In 1998, the first paper about radiofrequency
ablation in thyroid disease was published by Solbiati et al
[1], reporting the initial experience for ablation in meta-
static lymph nodes from papillary thyroid cancer. More
recently, radiofrequency ablation has also been shown to
relieve compressive symptoms and cosmetic problems
caused by benign thyroid nodules. Complications are not
evident in benign thyroid nodules and recurrent thyroid
cancer. The purpose of this review article is to provide in-
formation about the basic principles of radiofrequency
ablation, as well as a summary of previously published
clinical research about radiofrequency ablation in nodular
thyroid diseases. Possible complications and other safety
issues are also reviewed in each section.Basic principles of radiofrequency ablation
What is radiofrequency ablation?
Radiofrequency ablation is a technique to destroy tissues
with heat generated from high-frequency alternating cur-
rent. The alternating current is created by a radio-
frequency generator. The electrode and grounding pads are
both connected to the generator, with the electrode
inserted into the ablation target and grounding pads
attached to the body surface, mostly at both thighs. In that
way, the electrical conducting circle is formed. When the
generator is powered on, the alternating electric current
oscillating between 200 kHz and 1200 kHz [2] in the elec-
trode causes nearby tissue ion agitation, which can create
frictional heat. With that heat, the electrode can cause
target tissue coagulation necrosis. The grounding pads are
large dispersive electrodes that can let the current go
through the patient without causing significant heat as in
the electrode tip. For complete target tissue coagulation, a
higher temperature generated in the electrode needs less
time to create sufficient necrosis. When the temperature is
between 60 C and 100 C, tissue coagulation is noted
almost immediately. When the temperatures fall between
50 C and 52 C, it takes 4e6 minutes to create irreversible
cellular damage. If the temperature is just 46 C, >1 hour is
necessary to ablate the tissue successfully [3e5]. However,
the higher temperature is not always better for ablation.
When the temperature is higher than 100 C, it results in
adjacent tissue vaporization and carbonization [2].
Although the heat created by the electrode damagessurrounding tissue quickly, tissue more remote from the
carbonized or vaporized tissue is a heat insulator that
prevents heat conduction from the electrode to the pe-
ripheral tissue, which results in a smaller ablation zone and
is unfavorable for the treatment of malignant tissue.Evolution of electrodes
In an earlier study, the maximum coagulation zone pro-
duced from a conventional monopolar electrode is no more
than 1.6 cm in diameter [6]. However, the target lesion
such as hepatoma is usually >2 cm in diameter. Thus,
several strategies have been tried to improve the ablation
volume in larger tumors, such as modification of the elec-
trode design or a different generator program setting to
achieve better energy deposition. The first strategy is
multiprobe arrays, which includes the use of multiple free-
standing conventional radiofrequency electrodes in an
array [7]. This design has evolved into hooked electrodes,
available from two commercial vendors, RITA and Radio-
therapeutics [8,9], which allows the deployment of an array
of multiple, curved wires in the shape of an umbrella from a
single 14 gauge or 16 gauge cannula. With such electrodes,
the ablation diameter can be as large as 3.5 cm in human
liver in vivo [10].
Another approach to increase ablation volume is the
introduction of the internally cooled electrode [11,12].
Such electrodes have two hollow lumens that permit
continuous internal cooling of the tip with cooled water,
which can prevent overheating of the electrode tip and
keeps the temperature at no more than 90 C. As we have
mentioned previously, high temperatures may cause tissue
boiling and charring that interfere further with heat con-
duction. The internally cooled electrode can produce tissue
coagulation of around 2.8 cm in diameter for metastatic
hepatocellular carcinoma in clinical practice [13]. The next
step to obtain a larger ablation volume is the development
of clustered electrodes, which can apply radiofrequency
current to a cluster of three closely spaced electrodes. It
offers the potential of >3 cm coagulation diameter at a
single treatment session. In a preliminary report, radio-
frequency ablation using the cluster electrode technique
induced coagulation necrosis of 5.3 cm in diameter in sol-
itary intrahepatic colorectal metastases [14].
Other strategies to improve ablation efficacy include
bipolar arrays and pulsed application of radiofrequency
energy. Bipolar array means to place a ground electrode
within approximately 4 cm of the active electrode. It in-
creases the ablation volume a little, but the induced
coagulation is elliptical rather than spherical in cross-
section [15], which is not favorable for most tumor abla-
tion. Pulsing of radiofrequency energy is not a modification
of the electrode but to program the radiofrequency
generator to output periods of high energy rapidly alter-
nated with periods of low energy. If an appropriate balance
between high and low energy deposition is achieved,
preferential tissue cooling occurs adjacent to the electrode
to prevent the adverse effects of tissue charring and
boiling. In that way, a greater volume of tissue coagulation
will be achieved with the same electrode [16].
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and thyroid gland
The earliest experience of radiofrequency ablation was to
ablate the aberrant neurofibril bundle in symptomatic car-
diac arrhythmia [17]. Itwas also introduced for the treatment
of hyperactive neurologic foci or other neurologic disorders
[18]. In suchdiseases, it only needs creation of a precise small
region of coagulation. Thus, the earlier conventional
monopolar single electrode is adequate for that purpose. The
ablation technique has then been used to treat a diversity of
neoplasms, such as osteoid osteoma, primary andmetastatic
liver tumor, renal cell carcinoma,prostate cancer, andbreast
cancer percutaneously under the guidance of images, or
intraoperatively. In thepast twodecades, theprincipal use of
radiofrequency ablation was for liver malignancies, both
primary and secondary. A lot of research related to the
development and improvement of radiofrequency tech-
niques to treat liver cancer with satisfactory results has been
published [19]. The strategy to destroy a malignant lesion
completely is different from the treatment of cardiac
arrhythmia. This means that the ablation-induced necrosis
covers the entire tumor and should also reach cytotoxic
temperatures to kill all cancer cells. Therefore, the evolution
of electrodesmentioned in the previous section is just to fit in
with the requirement for complete ablation.
Benign or malignant nodular thyroid diseases are com-
mon. The prevalence of thyroid nodules has been reported
as 4e8% of adults by palpation, 10e41% by ultrasound ex-
amination, and 50% by pathologic examination at autopsy
[20]. Local surveillance in Taiwan has also shown that adult
goiter prevalence was 19.4% in men, 33.6% in women, and
estimated to be 25% in the total population [21]. If the
nodule is malignant or benign but causes compressive
symptoms, surgery is usually a better choice to remove the
nodule effectively. If the patient has primary thyroid cancer,
surgery is always the first choice. In some situations, if
recurrent thyroid cancer is detected several years after
primary surgical intervention, but the patient is not suitable
for another session of surgery due to comorbidity, a
nonsurgical and minimally invasive treatment modality is
needed as an alternative. When it refers to benign thyroid
nodule but with compressive symptoms, surgical interven-
tion also has some disadvantages such as leaving scar tissue
in the neck. It also calls for a nonsurgical, minimally invasive
alternative for these patients who do not want to have sur-
gery. Ethanol ablation [22,23] and laser ablation [24] have
been tried previously in such scenarios. Radiofrequency has
also been introduced to ablate malignancy and begin thyroid
nodules. In 1998, the first paper about radiofrequency
ablation in thyroid diseasewas published by Solbiati et al [1].
Since that time, several papers had been published about
the efficacy for radiofrequency in thyroid glands. We review
the literature about radiofrequency ablation in thyroid
nodules. In reviewing the published literature, most authors
have reported that radiofrequency ablation is both effective
and safe when used to treat either benign thyroid nodules or
recurrent thyroid cancer. By searching on PubMed, there
were four articles about radiofrequency ablation in recur-
rent thyroid cancer, which included more than eight pa-
tients. There were also nine articles about radiofrequencyablation in benign thyroid nodules, ranging from solid,
mixed, cystic to autonomously functioning nodules. The
reviews and comparisons of these studies in malignant or
benign lesions are discussed in the following sections.
Radiofrequency ablation in recurrent thyroid
cancer
Papillary thyroid cancer, the most common subtype of thy-
roid cancer, has a good prognosis after standard treatment
of surgery followed by radioiodine therapy and adequate
thyroid hormone replacement. However, some patients may
have recurrent cancer in the previous surgical bed or
metastasis to local regional lymph nodes. If the recurrent
disease is resistant to radioiodine therapy or difficult to
reoperate due to scar tissue formation or multiple comor-
bidity, radiofrequency ablation could be a good alternative.
Four studies [25e28] have shown encouraging results
about radiofrequency ablation for local recurrent or met-
astatic well-differentiated thyroid cancer. The baseline
tumor sizes ranged from 1.38 cm to 2.9 cm in diameter.
Radiofrequency ablation reduced the tumor volume and
serum thyroglobulin level significantly in most patients in
these studies. Baek et al [28] have reported a best average
volume reduction rate of 89.7%, with an average largest
diameter reduction rate of 76.1%. All researchers have
adopted the Radionics Cool-tip system as their ablation
system. This system is equipped with an internally cooled
electrode, with different lengths of the active tip ranging
from 1 cm to 2 cm. The tumor sizes were relatively small
compared with hepatocellular carcinoma, therefore, the
longer active tip with a larger ablation zone was not
absolutely an advantage. On the contrary, the shorter
active tip may prevent damage to organs adjacent to the
thyroid gland, such as the esophagus or recurrent laryngeal
nerve. For that reason, no researcher has used hooked
electrodes or clustered electrodes as the ablation tool.
Baek et al [28] have introduced an electrode produced by
Taewoong Medical, Seoul, Korea, which only has a 0.5 cm
active tip in the electrode. In that way, the ablation could
be performed more safely by easily handling the electrode.
In two earlier studies [25,26], patients received intrave-
nous sedation with fentanyl and midazolam prior to abla-
tion. In two other studies [27,28], patients were just
prescribed local anesthesia in the neck. This change may
have been due to the accumulative experience that showed
that the possible local discomfort is only minimal, so
generalized anesthesia is usually not necessary. The ablation
power, which was only available from Park et al [27] and
Baek et al [28], was relatively low at 10e90 W, as compared
with that of ablation in hepatocellular carcinoma. The
ablation time, which ranged from 2 minutes to 15 minutes in
these four studies without much difference, was usually less
than that in ablation for hepatocellular carcinoma. All of
these points show that ablation in liver and thyroid gland is
not the same because the thyroid is smaller than the liver.
Recurrent thyroid malignancy is also smaller as compared
with hepatocellular carcinoma. In the thyroid surgical bed or
local lymph nodes, they almost have no safety margins. For
that reason, we need a smaller electrode tip, lower power
output, and less ablation time to control so that the exact
Radiofrequency Ablation in Nodular Goiters 65ablation zone is just adequate to kill the tumor without
damaging the surrounding tissue. With regard to complica-
tions, all have reported good safety except for minor local
neck pain after ablation. Dupuy et al [25] and Monchic et al
[26] have reported two cases of vocal cord paralysis and
Baek et al has reported one [28].
Another interesting difference among these studies is the
ablation approach and technique. Park et al [27] and Baek
et al [28] introduced a transisthmus approach with a moving-
shot technique to ablate larger tumors. It was first described
forablationofbenign thyroidnodules [29,30], and isdifferent
from the fixed-electrode technique, which has been used to
ablate liver tumors. The transisthmus approach means to
insert the electrode from the isthmus to the lateral aspect of
a targeted nodule. In that way, the electrode and whole
ablation course can be monitored by a transverse ultrasound
view. Themoving-shot technique means that ablation can be
performed by continuously moving the electrode forward,
backward, upward, and downward to an untreated area. In
that way, Baek et al [30] have reported better ablation effi-
cacy with a lower complication rate.
Although the results of radiofrequency ablation in
recurrent thyroid cancer are promising, there were several
limitations to these studies, including the small number of
patients (only 45 in total) and the short follow-up period
(average, w2 years after ablation). There have been no
prospective randomized studies of radiofrequency ablation.
The long-term survival benefit after ablation is not clear, so
further long-term follow-up studies are necessary to
determine the precise role of this therapy if it is to play an
important role in the treatment of recurrent well-
differentiated thyroid cancer, and whether certain more
invasive surgical procedures can be replaced. The summary
of all these four studies are shown in Table 1 [25e28].Radiofrequency ablation in benign thyroid
nodules
It is not always necessary for benign nodules to undergo
surgery. However, when large nodules cause local
compression or cosmetic problems, they need further
treatment to relieve these symptoms. Levothyroxine sup-
pression therapy is a popular choice, but the outcome is not
satisfactory, especially in larger nodules [31]. Therefore,
other treatment modalities such as thermal ablation or
ethanol injection have been attempted in many studies to
reduce nodular volume.
There are more academic reports about radiofrequency
ablation for benign thyroid lesions than for malignant ones
(Table 2) [29,30,32e38]. The characteristics of the nodules
ranged from purely cystic nodules andmixed nodules to solid
ones. Both autonomous functioning (hot) nodules and cold
nodules were included among these trials, although not in
every report. The volume of target nodules was also larger
than that of malignant ones, ranging from 6 mL to 25 mL.
Interestingly, almost all of these papers came from two
countries: Italy [32,33] and Korea [29,30,34e38]. They used
different ablation systems and different approaches to erase
thyroid nodules. Deandrea et al [32] and Spiezia et al [33]
have used the RITA Starburst ablation system with hook-
expandable electrodes, via the longest axis of the thyroidgland to ablate the nodules. By contrast, studies from Korea
have used the Radionics Cool-tip ablation system with an
internally cooled electrode. Most of these studies also intro-
duced a transisthmus approach with moving-shot technique
to treat larger tumors. As in a published consensus statement
from the Korean Society of Radiology [39], this ablation
technique has become a standard procedure in Korea.
All nine of these studies only gave local anesthesia in the
neck, except for Kim et al [29], who administered intra-
venous sedation to 77% of the patients. The power output
was not available from the studies of Deandrea et al [32]
and Spiezia et al [33]. With the fixed-needle technique,
the nodules from these two studies were heated to
95e105 C for 10 minutes. The result of the volume
reduction rate in the follow-up period of up to 2 years was
reported as 47.7% by Deandrea et al and 79.4% by Spiezia
et al. Deandrea et al also showed a little more effective-
ness in volume reduction of hot nodules than cold ones
(48.4% vs. 44.7%). Some patients who had hot nodules could
be free from antithyroid drugs after ablation. The
improvement rate in the thyroid function test was reported
as 31% by Deandrea et al and 79% by Spiezia et al.
The power output and ablation time in seven studies
conducted in Korea [29,30,34e38] ranged from 20 W to
120 W and up to 30 minutes. It took more time for the
moving-shot ablation technique because this technique di-
vides thyroid nodules into multiple small conceptual abla-
tion units and performs ablation unit-by-unit by moving the
electrode. Theoretically, this technique will ablate nodules
more completely because the tumor shape is usually ellip-
soid rather than round [40]. After amean follow-up period of
around 12 months (up to 41 months), these studies showed a
better volume reduction rate, ranging from 75% to 92%, with
a slightly better result in cystic nodules than solid ones. The
autonomously functioning nodules also showed improve-
ment in the thyroid function test and radioiodine scan, and
four of nine patients had cold nodules and seven of nine
patients became nearly euthyroid [34]. It is worth
mentioning that Baek et al [36] conducted a prospective
study that compared the efficacy of radiofrequency ablation
versus control conditions. The control group had no resolu-
tion of nodule volume but increased slightly after 6 months.
In the radiofrequency ablation group, mean nodule volume
decreased from 7.5 mL to 1.3 mL after 6 months follow-up.
Another study [37] has demonstrated that radiofrequency
ablation for predominantly cystic nodules is as effective as
ethanol ablation (average volume reduction at last follow-
up, 92%). However, because ethanol ablation is much less
expensive than radiofrequency ablation, the authors have
suggested that ethanol ablation should be the first-line
treatment for predominantly cystic nodules.
The complications reported by Deandrea et al and Spiezia
et al were only minor local pain and edema after ablation,
which could be controlled easily by acetaminophen and
betamethasone, if necessary [32]. Oral antibiotics were not
routinely administered after the procedure. Some patients
had fever up to 38.8 C after ablation, which however
spontaneously returned to normal around 1 day after abla-
tion [33]. Major complications such as recurrent laryngeal
nerve injury, cutaneous burning, local infection or damage
to the vital structures of the neck, and severe damage
induced along the needle track were not observed. Hot
Table 1 Summary of studies about radiofrequency ablation in recurrent thyroid cancer.
Researcher Dupuy et al [25] Monchik et al [26] Park et al [27] Baek et al [28]
Year of publication 2001 2006 2011 2011
Tumor type Recurrent WTC in neck Recurrent WTC in neck Recurrent WTC in neck Recurrent WTC in neck
No. of pts 8 16 16 recurrent sites in 11 patients 12 recurrent sites in 10 patients
Baseline nodule
size, mean
Diameter 2.4 cm Diameter 1.7 cm Diameter 2.9 cm; volume 9 mL Diameter 1.38 cm; volume
55.5 mm3
Premedication IV sedation (fentanyl
and midazolam)
IV sedation (fentanyl
and midazolam)
Local anesthesia (xylocaine) Local anesthesia (xylocaine)
Approach Unavailable Unavailable Transisthmus or vertical Transisthmus or vertical
Ablation technique Fixed-needle Fixed-needle Moving-shot Moving-shot for large tumor;
fixed-needle for small tumor
Generator Radionics Cool-tip system Radionics Cool-tip system Radionics Cool-tip system Radionics Cool-tip system
Electrode 18G, 1 cm, 2 cm active tip 18G, 1 cm, 2 cm active tip 18G, 0.5 cm, 1 cm, 1.5 cm,
2 cm active tip
18G, 0.5 cm, 1 cm active tip
Mode Unavailable Unavailable Unavailable Unavailable
Power output Unavailable Unavailable Mean 67.3 W
Range 30e90 W
Mean 14.7 W
Range 10e40 W
Ablation time 2e12 min 2e12 min Mean 11.7 min
Range 1e22 min
Mean 6.7 min
Range 1e15 min
Follow-up period Mean 10.3 mo Mean 40.7 mo Mean 6 mo
Range 1e14 mo
Range 12e24 mo
Results (1) 6 of 8 pts: decreased serum
thyroglobulin level
(2) 6 of 8 pts:
no evidence of recurrence in
the treated LNs histologically
(3) No recurrent disease in
100% pts
(1) 11 of 16 pts:
decreased serum
thyroglobulin level
(2) 14 of 16 pts: no
recurrent disease
(1) Average volume reduction, 50.9%
(2) 7 of 11 pts (63.6%) relieved
local compressive symptoms
(1) Average volume reduction,
89.7%
(2) Average largest diameter
reduction 76.1%(3) Thyroglobulin
decreased in 7 of 10 pts
Complication 1 vocal cord paralysis
1 minor skin burn
1 permanent vocal
cord paralysis
1 minor skin burn
No reported major complications 1 dysphonia
IV Z intravenous; pts Z patients; WTC Z well-differentiated thyroid cancer.
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Table 2 Summary of studies about radiofrequency ablation in benign thyroid nodule.
Kim et al [29] Jeong et al [30] Deandrea et al [32] Spiezia et al [33]
Year of publication 2006 2008 2008 2009
Tumor type Benign cold nodules (solid
component 0e100%)
Benign nodules (solid
component 0e100%)
Benign nodules, hot or cold (solid
component >30%)
Benign nodules, hot or
cold (solid component >30%)
No. of pts 35 nodules in 30 pts 302 nodules in 236 pts 33 nodules (10 cold, 23 hot)
in 31 pts
94 pts (66 cold, 28 hot)
Baseline nodule
size, mean
Volume 6.3 mL Volume 6.13 mL Volume 27.7 mL Volume 24.5 mL
Premedication 23 in 30 pts (77%) required iv sedation.
All with local anesthesia
Local anesthesia (xylocaine) Local anesthesia (xylocaine) Local anesthesia (xylocaine)
Approach Longest axis Transisthmus Longest axis Unavailable
Ablation technique Moving-shot for large nodule;
fixed-needle for small nodule
Moving-shot Fixed-needle Fixed-needle
Generator Radionics Cool-tip system Radionics Cool-tip system RITA Starburst system RITA Starburst system
Electrode 18G, 1 cm active tip 18G, 1 cm active tip 9-hook expandable electrodes 4-hook expandable
electrodes, 14G to 3.5 cm
Mode Unavailable Unavailable Unavailable Unavailable
Power output Range 20e60 W Range 20e70 W Unavailable Unavailable
Ablation time >12 min 5e30 min (mean, 14 min) 6e10 min (at 95 C) 5e7 min (at 101e105 C)
Follow-up period Median 6.4 mo, range 1e18 mo Range 1e41 mo Mean 6 mo Range 12e24 mo
Results (1) Average volume reduction, 88.1%
(2) Mainly solid one: 82.2% at 9 mo
(3) Mixed/mainly cystic one: 90.0% at 9 mo
(4) Improvement of symptoms in 88% pts
(1) Average volume reduction
at last follow-up, 84.11%
(2) Complete disappearance
of index nodule, 27.81%
(3) More effective in cystic
lesion than solid lesions
(1) Average volume reduction
at 6 mo, 47.7%
(2) A little more effective in
hot nodules then cold ones
(48.4% vs. 44.7%)
(3) 10 pts with cold nodules
remained euthyroid
(4) 5 of 16 pts who had hot
nodules showed partial/full
remission of hyperthyroidism
(1) Average volume
reduction 2 y after RFA,
79.4%
(2) Nodules completely
disappeared in 88% pts
(3) Compressive symptoms
improved in 100% pts
(4) Hyperthyroidism
resolved in 79% pts with
hot nodules
Complications (1) 1 pt vocal cord palsy
(2) 1 pt hematoma
(3) 1 pt first-degree burn at the puncture site
(4) 1 pt mild to moderate pain at
the anterior neck for 2 d
(1) Voice change 1.3%
(2) Extrathyroid hematoma 2.1%
(3) Subclinical hyperthyroidism 1.3%
(4) 1 pt suspect tracheal injury (cough)
(5) 1 pt suspect brachial plexus injury
(4th finger numbness)
No reported major complications No reported major
complications
(continued on next page)
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Table 2 (continued)
Baek et al [34] Lee et al [35] Baek et al [36] Sung et al [37] Hun et al [38]
2009 2010 2010 2011 2012
Hot nodules (solid
component 60e100%)
Benign cold nodules (solid
component 10e50%)
Benign cold nodules
(solid component >50%)
Benign cystic nodules
(solid component <10%)
Benign cystic nodules (solid
component >50%)
9 pts 27 pts (post-EA 1e2 mo) 15 pts 21 pts 30 pts (15 for 1 session, 15
for 2 sessions)
Volume 14.98 mL Volume 4.2 mL (after EA but
prior to RFA)
Volume 7.5 mL Volume 10.19 mL Volume 13 mL (similar in
2 groups)
Local anesthesia (xylocaine) Local anesthesia (xylocaine) Local anesthesia (xylocaine) Local anesthesia
(xylocaine)
Local anesthesia (xylocaine)
Transisthmus approach Transisthmus approach Transisthmus approach Transisthmus approach Transisthmus approach
Moving-shot Moving-shot Moving-shot Moving-shot Moving-shot
Radionics Cool-tip system Radionics Cool-tip system Radionics Cool-tip system Radionics Cool-tip system Radionics Cool-tip system
17G, 18G, 1 cm active tip 18G, 1 cm active tip 18G, 1 cm active tip 18G, 1 cm active tip 17G, 18G, 1 cm, 1.5 cm active tip
Unavailable Unavailable Unavailable Unavailable Unavailable
Range 30e80 W Range 20e70 W Mean 32.4 W
Range 30e80 W
Range 30e100 W Range 30e120 W
Range 5e22 min Range 5e30 min Mean 15.5 min Range 3e32 min Unavailable
Range 6e17 mo Mean 21.2 mo
Range 6e38 mo
Range 6e8 mo Mean 19.5 mo Mean 6 mo
(1) Average volume
reduction at last
follow-up, 75%
(2) 4 of 9 pts had
cold nodules
(3) 7 of 9 pts became
nearly euthyroid
Average volume reduction after
additional RFA, 88%
Average volume reduction
after 6 mo, 83%
Average volume
reduction at last
follow-up, 92%
Average volume reduction after
1 session, 70.2%/2 sessions, 78.3%
(but no statistic significance)
No reported major complications No reported major complications No reported major complications No reported major complications No reported major complications
EA Z ethanol ablation; RFA Z radiofrequency ablation.
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Radiofrequency Ablation in Nodular Goiters 69nodules that turned into cold ones or remission of hyper-
thyroidism after ablation were the desirable results after
ablation. On the contrary, hypothyroidism after ablation to
cold nodules was not been reported in both studies.
Another seven studies [29,30,34e38] offered more de-
tails about the possible complication rate because they had
more study participants. Most of the reported complica-
tions were minor, such as various degrees of pain at the
ablated site, and pain radiating to the head, ear, shoulder,
or teeth during or after ablation. Such pain could be easily
controlled by reducing generator output during ablation or
by oral analgesics after the procedure. Few major compli-
cations have been reported in these studies. Jeong et al
[30] had the most participants in a single study and re-
ported voice change in 1.3%, extra-thyroid hematoma in
2.1%, and subclinical hyperthyroidism in 1.3% after abla-
tion. According to a recently published article from the
Korean Society of Thyroid Radiology [41], radiofrequency
ablation for 1543 thyroid nodules in 1459 patients con-
ducted in 13 thyroid centers was surveyed. There were 48
complications in about 3.3% of all patients. The major
complications were voice changes in 15 patients, brachial
plexus injury in one patient, tumor rupture in three pa-
tients, and permanent hypothyroidism in one patient. The
minor complications were hematoma in 15 patients, skin
burn in four patients, and vomiting in nine patients. The
authors have concluded that the complication rate of
radiofrequency ablation in benign thyroid nodules is low,
but various complications may still occur. Therefore,
comprehension of the complications and training for abla-
tion techniques are necessary to prevent major complica-
tions. All nine of these studies are summarized in Table 2.
In conclusion, among these studies, radiofrequency
ablation, a minimally invasive procedure, has been shown
to be a safe treatment of nodular thyroid diseases. Hospital
admission is unnecessary. It also does not leave a scar in the
neck. It can effectively reduce the volume of benign thy-
roid nodules. When a patient has well-differentiated thy-
roid cancer, radiofrequency ablation can also be an
alternative treatment choice for those who are unable to
receive surgical therapy. The ablation system, ablation
technique, and parameters during ablation were not all the
same in previous studies. Some used a fixed-needle tech-
nique, but others used a moving-shot technique. Deandrea
et al [32] and Spiezia et al [33] adopted the RITA Starburst
system, but other researchers have used the Radionics
Cool-tip system [27,28]. Except for the studies conducted
by Dupuy et al [25], Monchic et al [26], Deandrea et al [32]
and Spiezia et al [33], most of these studies were published
by Korean researchers with patients from Korean hospitals
[27e30]. A consensus statement recently published by the
Korean Society of Radiology [39] has reviewed the moving-
shot technique with transisthmus approach. It shows some
evidence that this technique may be a better way for thy-
roid nodules ablation than the fixed-needle technique.
Finally, although major complications are rare, training for
ablation techniques and understanding of local anatomy
and possible complications is necessary. Perhaps, routine
use of radiofrequency ablation in thyroid nodules can be
expected if more prospective randomized studies are con-
ducted, data of long-term efficacy and safety are acces-
sible, and insurance coverage is available.References
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